BMO says Lilly’s latest FDA drama is manageable

Another day, another Lilly plot twist

Eli Lilly is having one of those weeks where the headlines read like a checklist of pharma problems and pharma wins. On the one hand, BMO said the company’s newly approved Foundayo treatment comes with post-marketing study requirements that are manageable — annoying, sure, but not the kind of thing that blows up the thesis.

BMO’s message: don’t overreact

The bank reiterated its Outperform rating and kept a $1,300 price target on the stock. Translation: yes, the FDA wants more follow-up work, but BMO doesn’t think it changes the bigger picture for Lilly’s pipeline, commercial momentum, or the fact that investors are still paying for a lot of future growth.

Why you should care

For a company already valued like a near-mythical pharma unicorn, small regulatory speed bumps matter mostly because they can nudge sentiment. If the market starts treating every FDA request like a five-alarm fire, you can get unnecessary volatility. If analysts keep framing these as routine hoops, the stock gets to keep living in its “expensive, but maybe worth it” lane.

The blood-cancer footnote

Also worth noting: Lilly said its Phase 3 BRUIN CLL-322 trial hit its primary endpoint, with Jaypirca plus venetoclax and rituximab improving progression-free survival in relapsed or refractory CLL/SLL. That’s the kind of clinical update that helps remind everyone this isn’t just a weight-loss story — Lilly is trying to win in more than one therapeutic aisle.

Big picture: the FDA may be adding chores, but Lilly’s growth narrative is still doing plenty of heavy lifting.